Literature DB >> 24445294

Commentary on "integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer." Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T, Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.: Cancer Cell 2013;23(2):159-70.

Aria F Olumi.   

Abstract

Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with "classical" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in 11 tumors diagnosed at young age, and pursued comparative assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs. Data from a validation cohort of>10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic "androgen-type" pathomechanism in EO-PCA.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445294     DOI: 10.1016/j.urolonc.2013.08.018

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  11 in total

1.  The cancer genome: from structure to function.

Authors:  Ad Geurts van Kessel
Journal:  Cell Oncol (Dordr)       Date:  2014-06       Impact factor: 6.730

Review 2.  The physiological role of Wnt pathway in normal development and cancer.

Authors:  Xiang Li; Maria A Ortiz; Leszek Kotula
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-29

3.  Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes.

Authors:  Francesca Demichelis; Levi A Garraway; Mark A Rubin
Journal:  Cancer Cell       Date:  2013-02-11       Impact factor: 31.743

4.  Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.

Authors:  Suk Hyung Lee; Daniel Johnson; Richard Luong; Zijie Sun
Journal:  J Biol Chem       Date:  2014-12-19       Impact factor: 5.157

5.  Alveolar injury and regeneration following deletion of ABCA3.

Authors:  Tara N Rindler; Courtney A Stockman; Alyssa L Filuta; Kari M Brown; John M Snowball; Wenjia Zhou; Ruud Veldhuizen; Erika M Zink; Sydney E Dautel; Geremy Clair; Charles Ansong; Yan Xu; James P Bridges; Jeffrey A Whitsett
Journal:  JCI Insight       Date:  2017-12-21

6.  p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.

Authors:  Christoph Burdelski; Tatsiana Dieckmann; Asmus Heumann; Claudia Hube-Magg; Martina Kluth; Burkhard Beyer; Thomas Steuber; Raisa Pompe; Markus Graefen; Ronald Simon; Sarah Minner; Maria Christina Tsourlakis; Christina Koop; Jakob Izbicki; Guido Sauter; Till Krech; Thorsten Schlomm; Waldemar Wilczak; Patrick Lebok
Journal:  Tumour Biol       Date:  2016-07-21

Review 7.  The genomic evolution of human prostate cancer.

Authors:  T Mitchell; D E Neal
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

8.  Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013".

Authors:  Stephanie E Combs; Jürgen Debus; Günter Feick; Boris Hadaschik; Markus Hohenfellner; Roland Schüle; Jens-Peter Zacharias; Malte Schwardt
Journal:  Radiat Oncol       Date:  2014-11-04       Impact factor: 3.481

9.  Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.

Authors:  Alexander W Wyatt; Fan Mo; Kendric Wang; Brian McConeghy; Sonal Brahmbhatt; Lina Jong; Devon M Mitchell; Rebecca L Johnston; Anne Haegert; Estelle Li; Janet Liew; Jake Yeung; Raunak Shrestha; Anna V Lapuk; Andrew McPherson; Robert Shukin; Robert H Bell; Shawn Anderson; Jennifer Bishop; Antonio Hurtado-Coll; Hong Xiao; Arul M Chinnaiyan; Rohit Mehra; Dong Lin; Yuzhuo Wang; Ladan Fazli; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  Genome Biol       Date:  2014-08-26       Impact factor: 13.583

10.  Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness.

Authors:  Yansheng Liu; Jing Chen; Atul Sethi; Qing K Li; Lijun Chen; Ben Collins; Ludovic C J Gillet; Bernd Wollscheid; Hui Zhang; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2014-04-16       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.